Natalizumab in cerebrospinal fluid and breastmilk of patients with multiple sclerosis

Jahr

2023

Autoren

Callegari I, Schneider M, Aebischer V, Voortman MM, Proschmann U, Ziemssen T, Lindberg R, Fischer-Barnicol B, Khalil M, Kappos L, Kuhle J, Sanderson NSR, Derfuss T.

Verlag

Ther Adv Neurol Disord. 2023 Jan 30;16:17562864221150040.

Link

https://doi.org/10.1177/17562864221150040

Natalizumab in cerebrospinal fluid and breastmilk of patients with multiple sclerosis

MS brain health quality standards: a survey on the reality in clinical practice in Germany

Best supportive care for patients with primary progressive multiple sclerosis (PPMS) in Germany prior to ocrelizumab treatment: Final results from the RETRO PPMS study

Harmonized Data Quality Indicators Maintain Data Quality in Long-Term Safety Studies Using Multiple Sclerosis Registries/Data Sources: Experience from the CLARION Study

Eculizumab Use in Neuromyelitis Optica Spectrum Disorders

Higher effect sizes for the detection of accelerated brain volume loss and disability progression in multiple sclerosis using deep-learning